N. Ampel

Publications749
h-index40
Citations6,568
Highly Influential Citations185
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Galgiani
  • 289 Publications • 14,006 Citations
  • D. Pappagianis
  • 215 Publications • 6,042 Citations
  • J. Blair
  • 159 Publications • 5,187 Citations
  • D. Stevens
  • 817 Publications • 48,122 Citations
  • Publications
  • Influence
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.
TLDR
This document focuses on three primary areas of concern: the endemic mycoses, including histoplasmosis, sporotrichosis, blastomycosis; fungal infections of special concern for immune-compromised and critically ill patients, including cryptococcosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; and rare and emergingfungal infections.
Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
TLDR
This poster presents a probabilistic procedure called a “shots fired” procedure called “spatially aggregating granuloma” that is able to be injected into the lining of the arteries of the digestive system and excites the immune system.
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.
TLDR
In this practice guideline, recommendations are organized to address actionable questions concerning the entire spectrum of clinical syndromes that can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications.
Practice Guidelines for the Treatment of Coccidioidomycosis
TLDR
Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity, which may include antifungal therapy, surgical debridement, or both.
Recent Advances in Our Understanding of the Environmental, Epidemiological, Immunological, and Clinical Dimensions of Coccidioidomycosis
TLDR
This review is a summary of the recent advances that have been made in the understanding of this pathogen, including its mycology, genetics, and niche in the environment.
Coccidioidomycosis as a Common Cause of Community-acquired Pneumonia
TLDR
If CAP develops in persons who travel or reside in Coccidioides-endemic regions, diagnostic evaluation should routinely include laboratory evaluation for this organism.
Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.
TLDR
In this practice guideline, recommendations are organized to address actionable questions concerning the entire spectrum of clinical syndromes that can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications.
Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area.
Emerging disease issues and fungal pathogens associated with HIV infection.
  • N. Ampel
  • Medicine, Biology
    Emerging infectious diseases
  • 1996
TLDR
Although the advent of oral azole antifungal drugs has made primary prophylaxis against fungal diseases in HIV-infected patients feasible, many questions remain to be answered before the preventive use of antifundal drugs can be advocated.
The diagnosis of coccidioidomycosis
  • N. Ampel
  • Biology, Medicine
    F1000 medicine reports
  • 18 January 2009
TLDR
A commercially available test for coccidioidal galactomannan antigenuria now exists and appears useful for immunocompromised hosts with severe disease.
...
1
2
3
4
5
...